ストックスクリーナーアプリを入手
10.65
7.04%
0.70
アフターアワーズ：
10.65
前日終値:
$9.95
開ける：
$10.0433
24時間の取引高:
4,934
Relative Volume:
0.80
時価総額：
$101.48M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.91%
1か月 パフォーマンス:
-26.45%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$10.01
$10.65
1週間の範囲:
$9.81
$11.13
52週間の値動き範囲:
$9.75
$22.63
Exozymes Inc Stock (EXOZ) Company Profile
EXOZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
10.65 | 101.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Exozymes Inc (EXOZ) 最新ニュース
eXoZymes Inc. Reports 2024 Progress and IPO Success - TipRanks
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewswire
eXoZymes appoints new chief commercial officer By Investing.com - Investing.com Canada
eXoZymes appoints Damien Perriman as Chief Commercial Officer - World Bio Market Insights
eXoZymes appoints new chief commercial officer - Investing.com
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewswire
Strategic Win: eXoZymes Taps 20-Year Biotech Leader to Drive Commercial Growth - Stock Titan
MDB Capital's Remarkable Growth: AUM Soars 2100%, New Platform Launch Drives Expansion - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewswire
AI Enzyme Pioneer EXOZ Reveals 2024 Financial Performance: Q4 Earnings Call Details - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - The State
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
MDB Capital's 2024 Financial Results: CEO to Reveal Full Year Performance and Strategic Outlook - StockTitan
Who's Winning the AI Data Center Patent Race? New Report Reveals Surprising Leader - StockTitan
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle. - Markets Insider
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce - Corsicana Daily Sun
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With C - StreetInsider
eXoZymes president, chairman Hayat transitions out of roles - MSN
EXoZymes, Inc. Announces Management Changes -February 21, 2025 at 04:37 pm EST - Marketscreener.com
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ExoZymes Inc. appoints new board member and chairman By Investing.com - Investing.com Nigeria
eXoZymes Announces Leadership Changes with New Appointments - TipRanks
eXoZymes and MDB Capital Announce Leadership Transition at - GlobeNewswire
ExoZymes Inc. appoints new board member and chairman - Investing.com
eXoZymes Inc. Announces Leadership Changes and Rebranding Following Transition from Invizyne Technologies - Nasdaq
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - GlobeNewswire
Exozymes (EXOZ) Income Statement & Balance Sheet 2025 - MarketBeat
eXoZymes Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
eXoZymes Inc Rings the Closing Bell - Nasdaq
Reynolds Consumer Products, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech’s New Frontier: Discover the “Exozymes Era” Revolutionizing Chemical Production - Mi Valle
The Dawn of an Era: eXoZymes Ushers in a New Age of Biotechnology - Jomfruland.net
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering - GlobeNewswire
Can This AI-Powered Enzyme Company Transform the Future of Biotech? Nasdaq's Newest IPO Makes Bold Claims - StockTitan
Decibel Expands General Admission Brand's International Footprint - The Globe and Mail
Triller Group Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
3 Travel Stocks That Show the Travel Boom Is Far from Over - The Globe and Mail
Semtech Shares Plummet on AI Server Woes—Is a Turnaround Ahead? - The Globe and Mail
Analysts See Buying Opportunity in NVIDIA Before Earnings - The Globe and Mail
Prediction: ASML Will Beat the Market. Here's Why. - The Globe and Mail
3 Consumer Staples ETFs for Stability in a Volatile Market - The Globe and Mail
GCL Global Holdings Ltd. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Positive week for Invizyne Technologies, Inc. (NASDAQ:EXOZ) institutional investors who control 42% of the company - Simply Wall St
Invizyne Technologies, Inc. will Change its Name to eXoZymes, Inc -February 12, 2025 at 12:00 am EST - Marketscreener.com
Invizyne Technologies, Inc. will Change its Ticker to EXOZ from IZTC -February 12, 2025 at 12:00 am EST - Marketscreener.com
Should You Forget AMD and Buy 2 Tech Stocks Instead? - The Globe and Mail
What’s in a Name: Out with Invizyne, In with eXoZymes - Genetic Engineering & Biotechnology News
Rebranding Invizyne to eXoZymes Signifies a Sustainable - GlobeNewswire
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ - MSN
Exozymes Inc (EXOZ) 財務データ
Exozymes Inc (EXOZ) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.48%
大文字化:
|
ボリューム (24 時間):